• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与胰高血糖素样肽-1（GLP-1）受体激动剂联合使用对估算肾小球滤过率（eGFR）低于30且伴有大量蛋白尿的2型糖尿病（T2D）患者肾脏结局的影响：病例系列研究

Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.

作者信息

Kuhadiya Nitesh D, Mahmood Israa

机构信息

Division of Endocrinology, Diabetes & Metabolism Renown Health, Reno & DECON (Diabetes & Endocrine Center of Nevada) Reno NV USA.

Division of Endocrinology, Diabetes & Metabolism Renown Health Reno NV USA.

出版信息

Clin Case Rep. 2021 Mar 9;9(4):2310-2316. doi: 10.1002/ccr3.4022. eCollection 2021 Apr.

DOI:10.1002/ccr3.4022
PMID:33936685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077383/
Abstract

Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m).

摘要

肾脏保护作用可能是钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2抑制剂）和胰高血糖素样肽-1受体激动剂（GLP-1RA）的类效应。同时使用时，可能会产生协同作用。这两种药物在高肾脏风险患者（估算肾小球滤过率在21至30毫升/分钟/1.73平方米之间）中使用也是安全的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/bc7c321f49ed/CCR3-9-2310-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/a93ff98f000b/CCR3-9-2310-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/9f6385884eb5/CCR3-9-2310-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/7bf1cd27d63b/CCR3-9-2310-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/bc7c321f49ed/CCR3-9-2310-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/a93ff98f000b/CCR3-9-2310-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/9f6385884eb5/CCR3-9-2310-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/7bf1cd27d63b/CCR3-9-2310-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eea/8077383/bc7c321f49ed/CCR3-9-2310-g002.jpg

相似文献

1
Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与胰高血糖素样肽-1（GLP-1）受体激动剂联合使用对估算肾小球滤过率（eGFR）低于30且伴有大量蛋白尿的2型糖尿病（T2D）患者肾脏结局的影响：病例系列研究
Clin Case Rep. 2021 Mar 9;9(4):2310-2316. doi: 10.1002/ccr3.4022. eCollection 2021 Apr.
2
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.预测 SGLT-2 抑制剂与 GLP-1 受体激动剂在 2 型糖尿病患者主要不良心血管事件疗效的特征：一项荟萃分析研究。
Cardiovasc Diabetol. 2023 Jun 28;22(1):153. doi: 10.1186/s12933-023-01877-6.
3
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.GLP-1 受体激动剂- SGLT-2 抑制剂联合治疗与急性心肌梗死后心血管事件：2 型糖尿病患者的观察性研究。
Cardiovasc Diabetol. 2024 Jan 6;23(1):10. doi: 10.1186/s12933-023-02118-6.
4
Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白2抑制剂联合使用——我们是否在实际应用中充分发挥了它们的潜力？
World J Diabetes. 2020 Nov 15;11(11):540-552. doi: 10.4239/wjd.v11.i11.540.
5
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对心肾结局的影响：23 项心血管结局试验的网络荟萃分析。
Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z.
6
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.与 GLP-1 受体激动剂相比，SGLT-2 抑制剂在 2 型糖尿病中的心血管和其他糖尿病相关结局：全国性观察性研究。
Cardiovasc Diabetol. 2021 Mar 22;20(1):67. doi: 10.1186/s12933-021-01258-x.
7
Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与胰高血糖素样肽-1（GLP-1）受体激动剂联合治疗2型糖尿病的代谢及心血管益处
World J Cardiol. 2022 Jun 26;14(6):329-342. doi: 10.4330/wjc.v14.i6.329.
8
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.SGLT-2 抑制剂与 GLP-1 受体激动剂联合治疗作为互补药物，可改善 2 型糖尿病的多器官缺陷。
Postgrad Med. 2019 Nov;131(8):555-565. doi: 10.1080/00325481.2019.1670017. Epub 2019 Oct 3.
9
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.胰高血糖素样肽-1受体激动剂与其他降糖药物对2型糖尿病患者心血管和肾脏的有效性：一项真实世界研究的系统评价和荟萃分析
Metabolites. 2022 Feb 15;12(2):183. doi: 10.3390/metabo12020183.
10
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.GLP-1RAs 和 SGLT-2is 是否可降低 2 型糖尿病女性的心血管事件？一项系统评价和荟萃分析。
Diabetes Metab. 2021 Feb;47(1):101160. doi: 10.1016/j.diabet.2020.05.002. Epub 2020 May 18.

引用本文的文献

1
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health.胰高血糖素样肽-1受体激动剂的作用不断扩展：改善代谢和心理健康方面的临床结局
Curr Issues Mol Biol. 2025 Apr 17;47(4):285. doi: 10.3390/cimb47040285.
2
Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.胰高血糖素样肽-1受体激动剂对肾脏参数的影响：一项随机对照试验的荟萃分析
BMC Endocr Disord. 2025 May 7;25(1):124. doi: 10.1186/s12902-025-01948-7.
3
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique.

本文引用的文献

1
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
2
The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.SGLT2 抑制剂对糖尿病患者心血管和肾脏结局的影响：系统评价和荟萃分析。
Cardiorenal Med. 2020;10(1):1-10. doi: 10.1159/000503919. Epub 2019 Nov 19.
3
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
2型糖尿病中胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白2抑制剂联合应用：一项基于名义群体技术的临床实践范围综述与专家见解
Diabetes Ther. 2025 May;16(5):813-849. doi: 10.1007/s13300-025-01722-x. Epub 2025 Mar 24.
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
4
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.度拉鲁肽对比甘精胰岛素治疗 2 型糖尿病合并中重度慢性肾脏病患者（AWARD-7）：一项多中心、开放标签、随机试验。
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14.
5
Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.艾塞那肽增加白细胞介素-1 受体拮抗剂浓度并诱导 Nrf2-Keap1 调控的抗氧化酶：与β细胞功能的相关性。
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1180-1187. doi: 10.1210/jc.2017-02343.
6
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.在 EMPA-REG OUTCOME 试验中对 CV 进行保护：“节俭型底物”假说。
Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.
7
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.能量代谢重编程能否解释 EMPA-REG OUTCOME 研究中有益的心脏肾脏结局？一个统一的假说。
Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.